CTLA4 and cancer: Immunotherapy with ICB uses monoclonal antibodies that target the inhibitory proteins CTL antigen 4 (CTLA-4) or programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) on T cells or cancer cells to unleash the immune response.